Jazz Pharmaceuticals Announces Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Jazz Pharmaceuticals (JAZZ) Reports In-Line Q2 EPS, Reaffirms FY Guidance
August 5, 2015 4:30 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $2.41, in-line with the analyst estimate of $2.41. Revenue for the quarter came in at $333.7 million versus the consensus estimate of $335.86 million.
Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.75, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015... More
